Projects / Programmes
Vpliv antitrombotičnih postopkov na funkcijo žilnih pristopov za hemodializo (Slovene)
| Code |
Science |
Field |
Subfield |
| 3.06.00 |
Medical sciences |
Cardiovascular system |
|
| Code |
Science |
Field |
| B007 |
Biomedical sciences |
Medicine (human and vertebrates) |
| B560 |
Biomedical sciences |
Urology, nephrology |
vascular access, hemodialysis, antihrombotic regimen, function
Researchers (11)
Organisations (1)
Abstract
Vascular eccess is crucial factor for hemodialysis treatment. Native arteriovenous fistula, grafts and large bore vein chateters are the most important vascular access for hemodialysis. The most important reason for malfunction or failure of vascular access is thrombosis. Incidence of thrombosis could be reduced by using antihrobotic procedures and drugs.
In the prospective clinical study which will be carried out in Dialysis Center, Department of Nephrology, University Medical Center Ljubljana, hemodialysis patients will be randomly divided in two groups after construction of arteriovenous fistula or graft. Group A will be consisted of patients which will be given antiaggregating drug ticlopidine and group B will be patients without antithrombotic medication after arteriovenous fistula or graft construction.
The running time and function of AV fistula or graft will be assesed.
We would like to check the hypothesis that antiaggregating drug ticlpidine improves patency and prolongs functioning time of AV fistula or graft.
Patients who will need central venous catheters (either as temporary or permanent vascular access) will be divided into two groups according to anticoagulant solution with which the catheter will be locked during the interdialytic period. In group A will be patients whose catheter will be locked by heparin and in group B patients having catheters locked with citrate.
The hypothesis is that citrate is as effective as heparin as concerns anticoagulant effect and is more suitable concerning side effects as systemic anticoagilation.
